BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 25667102)

  • 1. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
    Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
    Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
    Park B
    Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway.
    Ouyang Z; Zhai Z; Li H; Liu X; Qu X; Li X; Fan Q; Tang T; Qin A; Dai K
    Biochem Pharmacol; 2014 Aug; 90(3):276-87. PubMed ID: 24950468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
    Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
    PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice.
    Sung B; Murakami A; Oyajobi BO; Aggarwal BB
    Cancer Res; 2009 Feb; 69(4):1477-84. PubMed ID: 19190327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
    Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice.
    Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W
    J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.
    Ma X; Liu Y; Zhang Y; Yu X; Wang W; Zhao D
    Biochem Biophys Res Commun; 2014 Mar; 445(2):282-8. PubMed ID: 24491533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
    Sung B; Oyajobi B; Aggarwal BB
    Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
    Thummuri D; Naidu VGM; Chaudhari P
    J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.